Stockreport

Menlo Therapeutics’ Phase 2 Serlopitant Study for the Treatment of Chronic Pruritus Published in the Journal of the American Academy of Dermatology

MENLO THERAPEUTICS INC COMMON  (MNLO) 
Last menlo therapeutics inc common earnings: 3/3 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.menlotherapeutics.com/investor-relations
PDF REDWOOD CITY, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Menlo Therapeutics Inc. (NASDAQ:MNLO), a late-stage biopharmaceutical company focused on the development of ser [Read more]